Business
Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management
SHANGHAI, Sept 1, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare
About this update from Zhongchao Inc.
[{"type":"text","content":"SHANGHAI, Sept 1, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) (\"Zhongchao\" or the \"Company\"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from \"Medical-Pharmaceutical\" to \"Medical-Pharmaceutical-Patient.\" Utilizing its accumulated experiences in medical education and innovation, and extensive resources with medical professionals and pharmaceuticals, Zhongchao is well positioned to become a platform that provides patients with major disease management services.\nThe Company has implemented several strategic initiatives to transform to the new \"Medical-Pharmaceutical-Patient\" model. In 2021, Zhongchao launched patient management business focusing on the professional field of tumor and rare disease through its subsidiary Shanghai Zhongxin Medical Technology Co., Ltd. (\"Zhongxin\"), which was the important first step of the transform. The strategy to extend business model was driven by the increased demands of \"patient-oriented\" healthcare in China. Management have been closely observing and monitoring such service model that is to provide medical services and disease management tailored to individual patient and allow patient to actively initiate and participate in health management and disease treatment since its appearance in 2021. It is worth to mention that the Company's self-developed patient management system successfully improved Duration of Therapy (\"DOT\") by 40.4% for liver cancer patients, contributing to the maximum efficiency of drugs, successful treatment and longer patient survival terms, as compared to patients without using the management system, based on the data collected by the Company during a period from November 2017 to September 2021. As a result, the Company plans to continue the development of patient management services through Zhongxin.\nAs of now, Zhongxin provides comprehensive disease education and management services for tumor patients receiving treatment. Through services such as drug aids, disease follow-up visits, medication management, and cancer education promotion, Z...